Shilpa Medicare’s finished dosage form manufacturing facility, Unit IV, situated at Pharma SEZ, Jadcherla, Telangana state has undergone a GMP inspection by ANVISA, Brazil starting August 21, 2023. The inspection has concluded successfully on August 24, 2023 without any observations.
The facility is involved in manufacturing, packaging, labelling and testing of finished dosage forms (sterile injections and non?sterile oral solids) for the treatment of various forms of cancer and adjuvant therapy. This inspection is the third major regulatory inspection (after Russia and Canada), cleared by this Site in the past two years. This inspection and subsequent approval will allow the company for the commercial distribution of products in Brazil market and enable approval of new applications for Brazil market.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: